Renal cell cancer (RCC) has become a prototype example of the extensive intra-tumor heterogeneity and clonal evolution of human cancers. However, there is little direct evidence on how the genetic heterogeneity impacts on drug response profiles of the cancer cells. Our goal was to determine how genomic clonal evolution impacts drug responses. Finding from this study could help to define the challenge that clonal evolution poses on cancer therapy. We established multiple patient-derived cells (PDCs) from different tumor regions of four RCC patients, verified their clonal relationship to each other and to the uncultured tumor tissue by genome sequencing.
Novelty and Impact
The comparison of drug responses among multiple variants of patient-derived cells (PDCs) exhibited the impact of intra-tumor genomic heterogeneity, as the individual PDCs from different tumor regions showed distinct drug sensitivity profiles. These data illustrate an approach that could facilitate the design of effective personalized drug combinations needed to target multiple subclones in cancer and for elucidating pharmacogenomic biomarkers.
Although the genotype-phenotype for familial medullary thyroid carcinoma (FMTC) is well studied, only a few low susceptibility risk loci have been identified for familial non-medullary thyroid carcinoma (FNMTC). Here, the authors screened and identified a novel susceptibility gene, MAP2K5, as a contributor to FNMTC. The data revealed that MAP2K5 variants A321T or M367T can activate the MAP2K5-ERK5 pathway, alter downstream gene expression, and subsequently induce thyroid epithelial cell malignant transformation. The study highlights the potential of MAP2K5 to be used for molecular diagnosis as well as to improve clinical management of deleterious MAP2K5 mutation-carriers.
Introduction
Genomic and transcriptomic studies have shown significant inter-and intra-tumor heterogeneity (ITH) in clear cell renal cancer (ccRCC) [1] [2] [3] . The discovery of inactivating Von Hippel-Lindau (VHL) mutations and aberrant mTOR/PI3K pathway regulation has provided key concepts for targeted treatments in ccRCC. The tumor suppressor VHL is mutated in up to 90% cases and leads to disruption of HIF levels affecting angiogenesis, genomic integrity, glycolysis and anabolic biosynthesis 4, 5 .
Deregulation in PI3K/AKT/mTOR pathway is also a consistent feature in ccRCC, influencing tumor progression through facilitating cellular growth and proliferation 6 .
Genes involved in histone modification and chromatin remodeling such as PBRM1, SETD2 and KDM5C are also often mutated in ccRCC 7, 8 . Despite the presence of common and consistent driver mutations in ccRCC, the variability in the drug responsiveness from one patient to another is still a major challenge 9 . This could be attributed to the presence of multiple distinct tumor subclones 10 .
Functional studies based on model systems to recapitulate genetic and phenotypic characteristics of the patient profile such as patient-derived xenograft (PDX)/tissue grafts (TG), organoids and patient-derived cultures that have recently been established from RCC [11] [12] [13] [14] [15] . TG models were generally well-characterized based on histology, gene expression and genomics, and are known to retain regional ITH 13 . TG models only allow for small scale drug testing studies, however, may recapitulate the drug responsiveness in patients 12, 15 . A study on a single patient"s PDX models derived from a primary and a lung metastatic sample showed noticeable variation in drug response profiles inferred from the single cell RNA-sequencing (scRNA-seq) of the paired samples, and underlined the impact of ITH in RCC 16 . In contrast, 2D primary cell models, provide for material towards more systematic drug tests, but are often challenging due to over-representation of normal cells 13 . In addition, these models are often established from single sites not representing the complexity of the disease.
Therefore, studies of the inter-and intra-patients" heterogeneity in drug responses due to subclones present at distinct sites remains an unanswered question at the research bench as well as in the clinic 10, 17 .
Here, we developed representative patient-derived cells (PDCs) from normal and (multiple) cancerous RCC tumor regions using conditional-reprogramming-cell-
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technology 18, 19 . The genomic profiles and drug testing data were compared with each other and to the original tumor features. We reconstructed phylogenetic trees based on mutations that inferred early-or late-stage events in the cancer progression.
Comprehensive drug profiling identified vulnerability of the PDCs against the drugs that hit major axis of action in RCC including established targeted therapies such as temsirolimus. It also showed distinct drug-response profiles in PDCs from the primary, invasive infiltrating vena cava and adrenal metastatic sites of the same patient.
Material and Methods

Patients and tissue processing
Renal tissue was obtained from four renal cancer patients that operated with open nephrectomy, at Helsinki University in the urological biobank initiative Hospital (Helsinki Urological Biobank, HUB), with approved informed consent (Dnro 263/13/03/02/2011; 379/13/03/02/2012 and Dnro § 212) ( Table 1) . Pieces of kidney tissue from the cancerous and normal regions of the kidney was selected by a boardcertified pathologist and was processed as illustrated in Fig. 1 . The amount of normal and malignant cells (including inflammation level and matrix/stromal content) in the parental tissue was evaluated through hematoxylin and eosin staining by the pathologist from tissue sections adjacent to the section used for patient-derived cells (PDC) establishment ( Supplementary Table S1 ).
Establishment of PDCs
We generated a total of 11 PDCs from four renal cancer patients derived tissues; normal region (n=4), localized/primary-tumor (n=4), invasive/infiltrating vena cava (n=2), adrenal gland metastatic sites (n=1). Cultures were established using conditional-reprogramming-cell-technology (CT) 18, 19 . Briefly, cells were isolated from the original tissue after chopping into small pieces and with collagenase (40 units/ml) treatment for 2-4 hours. The suspension put into culture dish having 30-50% confluent irradiated Swiss 3T3 fibroblast feeder cells (J2 strain). The co-cultured maintained in in F-medium (3:1 (v/v) constitutes of F-12 nutrient mixture (Ham) -DMEM (Invitrogen), 5% FBS, 8.4 ng/mL cholera toxin, 0.4 µg/mL hydrocortisone, 10 ng/mL EGF, 24 µg/mL adenine), 5 µg/mL insulin, and 10 µM ROCK inhibitor (Y-27632, Enzo Life Sciences, Lausen, Switzerland). Separation of 3T3-cells from the PDCs during passaging was done using differential trypsinization. Drug testing was performed between 2-6 weeks after the initiation of the culture, and at the same time cells were collected for other experiments and characterizations that were used for immunological staining, exome/whole genome sequencing. The passage numbers and duration of culture of each PDCs at the time of these experiments are described in supplementary Table S2 .
Exome sequencing
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The DNA extraction from the PDCs was done at the same passage as performing the drug sensitivity testing, i.e., 3-6 weeks after the establishment of the cultures. The extraction of genomic DNA from original tissues, PDCs and germline control blood cells was done using the DNeasy Blood & Tissue kit (Qiagen, Hilden, Germany).
Exome capture was performed using the Nimblegen Agilent SureSelect v5 capture kit (Agilent Technologies, Santa Clara, CA, USA). Sequencing was executed using a HiSeq 2500 instrument (Illumina, San Diego, CA, USA). 4×10 7 and 1×10 8 2×100-bp paired-end reads were sequenced per sample, respectively. Lists of somatic point mutations from parental tissues and PDC samples from the same patient were compared to each other to identify any mutations shared between the primary and cultured cells (p>0.05). The higher amount of somatic mutations called from the PDCs compared to primary tumor tissue samples (particularly RCC.1 primary cancer/vena cava and RCC.3 primary cancer) was most likely due to mouse DNA contamination from 3T3 cells that were co-culture as feeder cells for PDC.
Phylogenetic analysis of tumor and PDC
To construct the phylogenetic cell lineage tree, we adapted a computational method LICHeE (Lineage Inference for Cancer Heterogeneity and Evolution) 20 . These visualizations were reconstructed by utilizing mutational load of all the samples.
Excessive nodes with potential mouse contaminating mutations were removed from the final trees. Mutation present in each node are provided in the supplementary file S5. Parameters used for analysis are following.
Drug sensitivity testing
The PDCs established from the patient samples were cultured for 2-6 weeks and used for drug testing with 461-528 approved and investigational oncology drugs ( Supplementary Table S6 ) 18, 21 . The library consists of targeted compounds, such as kinase inhibitors, epigenetic modifiers, differentiating agent, metabolic inhibitors as well as chemotherapeutics. Briefly, PDCs were added to the drug containing plates, in
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five different concentrations (normally within 1nM -100uM concentration range) and let them grow for 72 h. The cell viability was measured with CellTiter-Glo (CTG, Promega, Madison, WI, USA). The raw data was further processed to calculate drug efficacies of individual drugs.
Statistical analysis
The percentage inhibition for each drug was calculated by normalizing the CTG raw value of each wells to negative control, dimethyl sulfoxide (DMSO, 0.1%) and positive control, benzethonium chloride (BzCl, 100 μM). The data points obtained from dose-response percent inhibition was fitted into a four-parameter logistic model to calculate IC50, slope, top and lower asymptotes to quantify the drug response. The calculations were executed through a multi-parameter area under the curve sensitivity method named, the drug sensitivity score (DSS) 21, 22 . To focus on the drugs with clear effects or lack thereof, we applied a DSS value of 5 as a cut-off. The combined doseresponse curve fits illustrated in Fig 
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Results
Phenotypic characterization of patient-derived cells and tumor tissue
Four RCC patients (RCC.1-4), a total of seven malignant and four normal regions were used for establishment of PDCs ( Fig.1) . Three of the patients had ccRCC (RCC.1, 3-4), while RCC.2, had a poorly differentiated mixed histology of ccRCC and collecting-duct-carcinoma (Table 1) . Altogether eleven PDCs were generated with co-culture of primary cells with irradiated 3T3-feeder cells, and Rho/Rockkinase-inhibitor (Y-27632) supplemented in F-medium 18, 19 . The histopathological analysis and phenotypic retention of PDCs were assessed by immuno-histochemical staining of carbonic anhydrase IX (CA9/CAIX) expression ( Supplementary Fig. 1-2 ).
Several studies have shown that CAIX is constitutively overexpressed in ccRCC 23 , and has been used to establish the relevance of ex vivo cancer models 13 . In our analysis, a significantly higher protein expression of CAIX was quantified in most cancerous tissues as compared to the normal ( Supplementary Fig. 2C ). The cancerous PDCs derived from RCC.1-2 and (metastatic) RCC.3 displayed comparable amounts of CAIX expression to their tissue of origin. An increased CAIX expression may also representing the general hypoxic (ex vivo) environment as PDCs derived from benign tissue were also exhibiting higher CAIX in contrast to their parental tissues.
The PDCs retained copy number alterations and somatic mutations present in the original tumor tissue
Comparison of parental tumor tissue and corresponding PDCs showed several shared cancer-specific deletions and amplifications at multiple chromosomal regions ( Fig. 2A-C, Supplementary Fig. 3 ). Some of these shared exact break-points highlighting the clonal relation between the PDCs and their originating tissue. Patients in this study carried recurrent alterations in RCC reported by The Cancer Genome Atlas (TCGA) 2 . For example, the 14(del) and 3p(del) that are the most frequent site of nonrandom aberrations ( Supplementary Fig. 3A ) with the 3p harboring frequently mutated tumor suppressor genes VHL, PBRM1, SETD2, and BAP1 24 . Additionally, we observed Copy Number Alterations (CNAs) in several genes of known relevance to RCC including EGFR amplification and CDKN2A/B deletion ( Fig. 2C) 2, 6 . In a recent study, deletion at 9p and 14q have been shown as putative biomarker of metastasis in ccRCC 25 . Interestingly, these CNAs are retained by both cancerous
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PDCs of RCC.1 and subclonally in metastatic RCC.3 tissue/PDCs ( Fig. 2A -C, Supplementary Fig. 3 ).
Next, we compared somatic mutations in the tumor tissue and the PDCs to recurrent RCC mutations in the TCGA data ( Fig. 2D , Supplementary Table S4) 
Clonal relationship between tumor tissues and PDCs based on the somatic mutation patterns
We inferred cell lineage and clonal relationships between the different tumor sites and their derivative PDCs by reconstructing cancer phylogenetic trees for each RCC patient 20 (Fig. 3, Supplementary Fig. 4 ). The data indicated a branched evolution, which is consistent with the previously reported studies 3 . The RCC.1 demonstrated a common ancestral clone, harbored 36 truncal mutations that gave rise to all subsequent clones present in both primary and vena cava cancer tissue and PDCs thereof. Subsequently, four additional mutations were acquired by the tumor in the vena cava tissue resulting in a branch away from the primary tumor. The PDC models from vena cava tumor and the primary tumor retained the first and second ancestral subclones thereby recapitulating clonal evolution of the originating tumor tissue ( Fig.   3A) . Similarly, the common ancestor clone in RCC.3 had nine truncal mutations, and additional events resulted in subsequent branching out in a chronological order from the primary tumor, the tumor infiltrating vena cava, and the metastatic tumor tissue ( Fig. 3B) . The phylogenetic tree also suggested that the metastatic PDCs and tumor tissue accumulated most of these somatic mutations and retained a close clonal relationship with each other. The RCC.2 cancer PDCs share four mutations including VHL with their originating tumor tissue ( Supplementary Fig. 4A ). In contrast, RCC.4
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was classified as a poorly representative cancer model since the tissue and derived PDCs did not carry any common mutation ( Supplementary Fig. 4B ).
Comprehensive drug testing showed distinct response profiles among PDCs derived from different regions of a patient's cancer tissue
The PDCs were subjected to drug testing with at least 460 approved and investigational oncology-drugs to evaluate their sensitivity profiles ( Supplementary   Table S6 ). RCC.1 and RCC.3 PDCs allowed for intra-patient comparison of drug profiles and distinct sensitivities for several key oncology drugs were observed for PDCs from the primary-tumor, vena cava tumor and for RCC.3 in the metastatic-site ( Fig. 4, Supplementary Fig. 5 ). Specifically, in RCC.1 primary cancer PDCs showed efficacy for ZSTK474, a PI3K-inhibitor as well as JQ1 and OTX015 that are both bromodomain and extra-terminal (BET) protein inhibitors (Fig. 4A, D) . The RCC. Supplementary Table S6) 26 . Interestingly, pazopanib a multi-kinase-inhibitor approved for RCC treatment showed sensitivity in RCC.1 vena cava PDCs 27 . The effective drugs for RCC.3 primary cancer PDCs included docetaxel whereas, the vena cava PDCs showed specific responses to VEGFR-inhibitors, tivozanib and regorafenib (Fig. 4E) . The former has recently been approved by the European Medicines Agency for the treatment of RCC and the latter has been approved for treatment of colorectal cancer ( Supplementary Table S6 , 27 . Interestingly, RCC.3 metastatic PDCs showed increased sensitivities to three topoisomerase-inhibitors camptothecin, SN-38 and topotecan. Other drugs showing efficacy were BMS-754807 an IGF1R-inhibitor and gemcitabine, a nucleoside analog that is approved for the treatment of several cancers ( Fig. 4B-C, E) 27 . In summary, our results showed both shared drugs sensitivities for actionable drugs within different subclonal PDC models, as well as a distinct response profiles that need to be taken into consideration for treatment strategies.
Genomic intra-tumor heterogeneity linked to the drug response profiles
To explore potential associations between drug sensitivities and genomic vulnerabilities, we highlighted the genetic alterations (GAs) including CNA and non-Accepted Article synonymous somatic mutations in the phylogenetic trees along with the drug responses of the PDCs (Fig. 5 ). The two PDCs derived from RCC.1 malignant tissue harbored truncal GAs (Fig. 5A) , and exhibited shared sensitivity towards investigational drugs predominantly from mTOR/PI3K pathways (Fig. 5B ) of which omipalisib, AZD2014 and dactinomycin have been tested in the clinical trials for their efficacies in RCC patients ( Supplementary Table S6 ) 28 . The primary cancer PDCs displayed additional mutations in bromodomain-containing-1-gene (BRD1) as well as PBRM1. BRD-containing-proteins that regulate the transcriptional activities are frequently dysregulated in cancers, and can be targeted with BET-inhibitors 29 .
Interestingly, we observed specific sensitivity of the primary tumor PDCs to the three BET-inhibitors, IBET-151, JQ1 and OTX015 (Fig. 5D ). In addition, EGFR-inhibitors (gefitinib, erlotinib, afatinib) and other kinase inhibitors (rigosertib and dasatinib) that exhibited selective responses in these PDCs are approved oncology drugs for other malignancies and have also been investigated in RCC patients ( Fig. 5D , Supplementary Table S6 ). The RCC.1 vena cava PDCs were sensitized to tivozanib and pazopanib in addition to investigational drugs (Fig. 5E ).
All PDCs from RCC.3 displayed truncal mutations on BRD4 and IGFN1 and showed shared sensitivity to mTOR/PI3K, BET and topoisomerase-inhibitors ( Fig. 5F-G ).
BRD4 is a major target for BET-inhibitors and therefore this results suggests a potential link with the vulnerabilities to the observed GA 29 . The RCC.3 PDCs separate into two sub-branches harboring distinct sets of mutations ( Fig. 5H-I) where the branch containing the primary cancer and adrenal metastatic PDCs show shared sensitivity to temsirolimus, gemcitabine and cabazitaxel (Fig. 5J) 27 . This branch showed further division into distinct clones by accumulation of mutations and interestingly the drug sensitivities are mostly novel, not found in previous or ongoing investigational trials for RCC patients, except for atorvastatin ( Fig. 5L-M) . In contrast, in the vena cava branch the PDCs were mostly sensitive to two VEGFRinhibitors, tivozanib and regorafenib, approved for other malignancies (Fig. 5N , Supplementary Table S6 ). In conclusion, our analyses reveal the complexity of genomic ITH in RCC and a spectrum of drug responses among the different subclones of PDCs obtained from multiple regions of cancer patient.
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Discussion
The heterogeneous drug responsiveness and resistance mechanisms of targeted drugs in RCC patients are poorly understood and required novel therapeutic targets and drugs. Our study on PDCs generated from advanced RCC tumors highlights how curative treatments and drug combinations preferably would need to target all subclones having unique drug response patterns. It also shows the limitation of single site sampling from each cancer that may underestimate the mutational landscape and variation in drug responses.
The PDCs generated in this study were often enriched for driver mutations and CNAs as compared to the uncultured parental tumor tissue. For example, the mutation frequency in VHL identified in RCC.1 increased from 7 to 28% in the localized tumor to the corresponding PDC, and from 33 to 64% in vena cava tumor tissue to PDCs 
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Recently, Kim et al., emphasized the variation in drug responses due to functional ITH examined through scRNA-seq of tissue/PDX of primary and metastatic samples 16 . The study further revealed the drug combination strategies to overcome the subclonal activation of multiple signaling pathways. Our analysis provides a proof of concept study showing that ITH can be functionally explored through comprehensive drug testing of multiple established PDCs. While shared, early genetic alterations in the trunk of the cancer phylogenetic tree may highlight common drug efficacies, the subsequent subclones with additional genetic alterations may lead to multiple distinct drug response patterns 10 . Thus, the analysis of multiple variants from a single patient provides significant insight for the pharmacogenomics analyses as compared to studies between diverse cancers with a different genetic background.
However, certain limitations are bound to the study that need to be kept in consideration for future studies. For example, subsequent overgrowth of normal cells in different culture system is repeatedly reported as a consistent challenge in the establishment and maintenance of cancer culture [31] [32] [33] . Though the growth advantage of normal over cancer cells in ex vivo condition is not clear, but a rapid induction of apoptosis in cancer cells has been proposed, likely due to their unstable genetic makeup 34 . Assurance of cancer-specific representation of PDC is important since a small populating of contaminating normal clones can also be enriched, as in the case of RCC.4. Since CR technology is powerful in expanding both normal and cancer cells and should therefore be used with care to validate the nature of established culture 35 . Cancer-specificity of RCC.3 primary cancer and vena cava PDC is also questionable due to absence of truncal VHL mutation in these cultures. However, both of these cells retained few shared mutations with their respective cancer tissues as shown in Fig.2 and Fig. 5 . Another limitation of these cultures is the inability of ex vivo drug testing to recapitulate in vivo scenarios for major targeted drugs such as anti-VEGFR in RCC due to absence of microenvironment/endothelial cells. Since drugs acting on VEGFR/PDGFR axis are acting on endothelial cells but not the tumor themselves 36 . Hence, VEGFR inhibitors (axitinib or sunitinib) did not show responses in the PDCs, while pazopanib had little impact (~20% cell inhibition) can be explained due to its additional multi-kinase inhibitory action or off-side effect (supplementary table 5). One missing aspect of the study is the sampling form the distant metastatic sites which is fundamental issue for clinical burden and the major Accepted Article target for systemic therapies. Though, these studies presented a proof-of-concept to highlight the cancer specific drug responses observed in ex vivo setting could provide inferences for drug repositioning and possibly in the future for individualized treatment options. However, further dedicated studies with higher number of patients with several (distant) metastatic samples and heterogeneous material would still be needed to confirm these interpretations.
The concept of simultaneous targeting the bulk tumor representing the trunk with a drug/surgery, and subclones with another specific drug has increased acceptance in clinical research 37 Frequencies were calculated based on number of tumor specific reads in the exome/whole genome sequencing. Accepted Article
